A5079394240- Sarcoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- Angiogenesis and VEGF in Cancer
- Cancer therapeutics and mechanisms
- Nanoparticle-Based Drug Delivery
- Peroxisome Proliferator-Activated Receptors
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Ovarian cancer diagnosis and treatment
- Cell Adhesion Molecules Research
- Cancer Research and Treatments
- Occupational and environmental lung diseases
- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Neuroblastoma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- PARP inhibition in cancer therapy
- Cardiac tumors and thrombi
- Mass Spectrometry Techniques and Applications
Mario Negri Institute for Pharmacological Research
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2016-2025
IRCCS Humanitas Research Hospital
2025
PharmaMar (Spain)
2007-2010
University of Milan
2010
University of Pavia
2010
Indena (Italy)
2007
Sigma Tau (Italy)
2007
Charité - Universitätsmedizin Berlin
2007
Hôpital Edouard Herriot
2007
Inflammatory mediators present in the tumor milieu may promote cancer progression and are considered promising targets of novel biological therapies. We previously reported that marine antitumor agent trabectedin, approved Europe 2007 for soft tissue sarcomas 2009 ovarian cancer, was able to downmodulate production selected cytokines/chemokines immune cells. Patients with myxoid liposarcoma (MLS), a subtype characterized by expression oncogenic transcript FUS-CHOP, highly responsive...
Lurbinectedin is a novel anticancer agent currently undergoing late-stage (Phase II /III) clinical evaluation in platinum-resistant ovarian, BRCA1/2-mutated breast and small-cell lung cancer. structurally related to trabectedin it inhibits active transcription the DNA repair machinery tumour cells.In this study we investigated whether lurbinectedin has ability modulate inflammatory microenvironment viability of myeloid cells tumour-bearing mice.Administration significantly selectively...
Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of tumors clinically defined by the lack estrogen, progesterone HER2 receptors, limiting use targeted therapies employed in other malignancies. Recent evidence indicates that c-MYC a key driver TNBC. The BET-bromodomain inhibitor OTX015 (MK-8628) has potent antiproliferative activity accompanied down-regulation several tumor types, demonstrated synergism with mTOR everolimus different models. aim this study was...
Abstract Mass Spectrometry Imaging (MSI) is a widespread technique used to qualitatively describe in two dimensions the distribution of endogenous or exogenous compounds within tissue sections. Absolute quantification drugs using MSI recent challenge that just last years has started be addressed. Starting from dimensional protocol, we developed three-dimensional pipeline study drug penetration tumors and develop new method by MALDI MSI. Paclitaxel concentration different were measured 3D...
Abstract The penetration of anticancer drugs in solid tumors is important to ensure the therapeutic effect, so methods are needed understand drug distribution different parts tumor. Mass spectrometry imaging (MSI) has great potential this field visualize organs and tumor tissues with good spatial resolution superior specificity. We present an accurate reproducible method investigate variation tumors. was applied study paclitaxel three ovarian cancer models histopathological characteristics...
Abstract Purpose: The formation of G-quadruplex structures at telomeric DNA sequences blocks telomerase activity, offering an original strategy to design and develop new antitumor agents. pentacyclic acridinium salt RHPS4 is one the most effective selective G4 ligands able rapidly disrupt telomere architecture, resulting in apoptosis cancer cells. Here, we studied therapeutic index its integration with chemotherapeutics preclinical model solid tumors. Experimental Design: antitumoral...
The antitumor activity of angiogenesis inhibitors is reinforced in combination with chemotherapy. It debated whether this potentiation related to a better drug delivery the tumor due antiangiogenic effects on vessel phenotype and functionality. We addressed question by combining bevacizumab paclitaxel A2780-1A9 ovarian carcinoma HT-29 colon transplanted ectopically subcutis nude mice IGROV1 orthotopically bursa mouse ovary. Paclitaxel concentrations together its distribution MALDI mass...
This study: (i) investigated the in vitro cytotoxicity and mode of action lurbinectedin (PM01183) Zalypsis® (PM00104) compared with trabectedin cell lines deficient specific mechanisms repair, (ii) evaluated their vivo antitumor activity against a series murine tumors human xenografts. The antiproliferative activity, DNA damage cycle perturbations induced by three compounds on tumor were very similar. Nucleotide Excision Repair (NER) cells approximately fourfold more resistant to...
Trabectedin is a marine natural product, approved in Europe for the treatment of soft tissue sarcoma and relapsed ovarian cancer. Clinical experimental evidence indicates that trabectedin particularly effective against myxoid liposarcomas where response associated to regression capillary networks. Here, we investigated mechanism antiangiogenic activity liposarcomas. directly targeted endothelial cells, impairing functions relying on extracellular matrix remodeling (invasion branching...
// Maria E. Riveiro 1 , Lucile Astorgues-Xerri Ramiro Vazquez 2 Roberta Frapolli Ivo Kwee 3, 5 Andrea Rinaldi 3 Elodie Odore 6 Keyvan Rezai Mohamed Bekradda Giorgio Inghirami 7, 9 Maurizio D’Incalci Kay Noel 10 Esteban Cvitkovic 1, Eric Raymond 11 Francesco Bertoni 12 Oncology Therapeutic Development, Clichy, France IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy Lymphoma and Genomics Research Program, IOR Institute of Research, Bellinzona, Switzerland 4 Dalle Molle...
One of the main hurdles in nanomedicine is low stability drug–nanocarrier complexes as well drug delivery efficiency region-of-interest. Here, we describe use film-forming protein hydrophobin HFBII to organize dodecanethiol-protected gold nanoparticles (NPs) into well-defined supraparticles (SPs). The obtained SPs are exceptionally stable vivo and efficiently encapsulate hydrophobic molecules. film prevents massive release encapsulated drug, which, instead, activated by selective SP...
Scarce drug penetration in solid tumours is one of the possible causes limited efficacy chemotherapy and related to altered tumour microenvironment. The abnormal extracellular matrix (ECM) together with blood lymphatic vessels, reactive stroma inflammation all affect uptake, distribution anticancer drugs.We investigated effect PEGylated recombinant human hyaluronidase PH20 (PEGPH20) pre-treatment degrading hyaluronan (hyaluronic acid; HA), main components ECM, improve delivery antitumor...
Abstract Platinum‐based chemotherapy is the first‐line treatment for different cancer types, and in particular, malignant pleural mesothelioma patients (a tumor histotype with urgent medical needs). Herein, a strategy presented to stabilize, transport, intracellularly release platinum IV (Pt ) prodrug using breakable nanocarrier. Its reduction, therefore activation as an anticancer drug, promoted by presence of glutathione neoplastic cells that also causes destruction carrier. The nanocage...
// Elisa Caiola 1 , Daniela Salles 2 Roberta Frapolli 3 Monica Lupi Giuseppe Rotella 4 Anna Ronchi 5 Marina Chiara Garassino 6 Nikola Mattschas Stefano Colavecchio Massimo Broggini Lisa Wiesmüller Mirko Marabese Laboratory of Molecular Pharmacology, Department Oncology, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy Obstetrics and Gynecology the University Ulm, Germany Cancer Environmental Health Sciences, Centro Nazionale Informazione Tossicologiche, Fondazione...
In order to investigate the mechanisms of acquired resistance trabectedin, trabectedin-resistant human myxoid liposarcoma (402-91/T) and ovarian carcinoma (A2780/T) cell lines were derived characterised in vitro vivo. Resistant obtained by repeated exposures trabectedin. Characterisation was performed evaluating drug sensitivity, cycle perturbations, DNA damage repair protein expression. vivo experiments on A2780 A2780/T xenografts. 402-91/T cells six-fold resistant trabectedin compared with...
The clinical success of small-molecule vascular disrupting agents (VDAs) depends on their combination with conventional therapies. Scheduling and sequencing remain key issues in the design VDA–chemotherapy treatments. This study examined antitumour activity ZD6126, a microtubule destabilising VDA, paclitaxel (PTX), microtubule-stabilising cytotoxic drug, influence schedule sequence efficacy combination. Nude mice bearing MDA-MB-435 xenografts received weekly cycles ZD6126 (200 mg kg−1 i.p.)...